Skip to main content

FDA & Regulatory

Orphan Drug Designation

Orphan Drug Designation (ODD) applies to therapies for rare diseases affecting fewer than 200,000 people in the U.S. It confers incentives including tax credits, fee waivers, and seven years of market exclusivity on approval.

Category
FDA & Regulatory
Abbreviation
ODD
BioSniper AIPage evidence connected

Prepared research question

How does Orphan Drug Designation affect the view of a biotech company in practice?

Run cited research

Traceable citations · Unknowns marked

Orphan Drug Designation (ODD) applies to therapies for rare diseases affecting fewer than 200,000 people in the U.S. It confers incentives including tax credits, fee waivers, and seven years of market exclusivity on approval.

Related terms

Learn more

From term to thesis rule

Investigate how Orphan Drug Designation changes a biotech thesis

Define when Orphan Drug Designation should count, block, or trigger a deeper check; BioSniper will compile that logic against available evidence.